Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
Soo RA, Wang LZ, Tham LS, Yong WP, Boyer M, Lim HL, Lee HS, Millward M, Liang S, Beale P, Lee SC, Goh BC. Soo RA, et al. Among authors: beale p. Ann Oncol. 2006 Jul;17(7):1128-33. doi: 10.1093/annonc/mdl084. Epub 2006 May 2. Ann Oncol. 2006. PMID: 16670205 Free article. Clinical Trial.
Phase I study of oral JM216 given twice daily.
Beale P, Raynaud F, Hanwell J, Berry C, Moore S, Odell D, Judson I. Beale P, et al. Cancer Chemother Pharmacol. 1998;42(2):142-8. doi: 10.1007/s002800050797. Cancer Chemother Pharmacol. 1998. PMID: 9654114 Clinical Trial.
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
Briasoulis E, Judson I, Pavlidis N, Beale P, Wanders J, Groot Y, Veerman G, Schuessler M, Niebch G, Siamopoulos K, Tzamakou E, Rammou D, Wolf L, Walker R, Hanauske A. Briasoulis E, et al. Among authors: beale p. J Clin Oncol. 2000 Oct 15;18(20):3535-44. doi: 10.1200/JCO.2000.18.20.3535. J Clin Oncol. 2000. PMID: 11032596 Clinical Trial.
Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experience and review of the literature.
Vardy J, Engelhardt K, Cox K, Jacquet J, McDade A, Boyer M, Beale P, Stockler M, Loneragan R, Dennien B, Waugh R, Clarke SJ. Vardy J, et al. Among authors: beale p. Br J Cancer. 2004 Sep 13;91(6):1045-9. doi: 10.1038/sj.bjc.6602082. Br J Cancer. 2004. PMID: 15316563 Free PMC article. Review.
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).
Yeo W, Boyer M, Chung HC, Ong SY, Lim R, Zee B, Ma B, Lam KC, Mo FK, Ng EK, Ho R, Clarke S, Roh JK, Beale P, Rha SY, Jeung HC, Soo R, Goh BC, Chan AT; Cancer Therapeutics Research Group (CTRG). Yeo W, et al. Among authors: beale p. Cancer Chemother Pharmacol. 2007 Feb;59(3):295-300. doi: 10.1007/s00280-006-0270-1. Epub 2006 Jun 17. Cancer Chemother Pharmacol. 2007. PMID: 16783579 Clinical Trial.
Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study.
Harnett P, Buck M, Beale P, Goldrick A, Allan S, Fitzharris B, De Souza P, Links M, Kalimi G, Davies T, Stuart-Harris R. Harnett P, et al. Among authors: beale p. Int J Gynecol Cancer. 2007 Mar-Apr;17(2):359-66. doi: 10.1111/j.1525-1438.2007.00763.x. Int J Gynecol Cancer. 2007. PMID: 17362313 Clinical Trial.
300 results